Coherus Biosciences Inc. (CHRS)
Summary
Coherus Oncology, Inc. (CHRS) Q2 2026 Earnings Call Transcript
Coherus Oncology, Inc. (CHRS) Q2 2026 Earnings Call Transcript
Coherus Oncology Q2 Earnings Call Highlights
Coherus Oncology NASDAQ: CHRS said it is approaching several clinical data disclosures in the second half of 2026, while reporting continued growth for its LOQTORZI treatment and lower operating expenses following the divestiture of its UDENYCA franchise.
Coherus Oncology (CHRS) Reports Q2 Loss, Misses Revenue Estimates
Coherus Oncology (CHRS) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of $0.08. This compares to a loss of $0.34 per share a year ago.
Coherus Biosciences Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Curtis Ellergodt Rothschild Investment LLC | 188 | $302.2 | $278.24 | -$23.96 | -7.93% |
| MA mason adams PVG ASSET MANAGEMENT Corp. | 133,235 | $225,167.15 | $198,520.15 | -$26,647 | -11.83% |
| BG Bart Gancher Intech Investment Management LLC | 31,607 | $27,446.22 | $40,140.89 | $12,694.67 | 46.25% |
| JM John Malone Amundi | 10,994 | $90,639.87 | $13,632.56 | -$77,007.31 | -84.96% |
 Joseph Castro Nuveen LLC | 250,749 | $305,499.34 | $310,928.76 | $5,429.42 | 1.78% |
Coherus Biosciences Inc. (CHRS) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Coherus Biosciences Inc. ever had a stock split?
Coherus Biosciences Inc. Profile
| Biotechnology Industry | Healthcare Sector | Dennis Lanfear CEO | NASDAQ (NMS) Exchange | 19249H103 CUSIP |
| US Country | 144 Employees | - Last Dividend | - Last Split | 6 Nov 2014 IPO Date |
Overview
Coherus BioSciences, Inc. is a biopharmaceutical entity focused on the inception, development, and commercialization of innovative cancer therapies, primarily servicing the United States. Initially founded as BioGenerics, Inc., the company underwent a rebranding in April 2012, adopting its current name, and is headquartered in Redwood City, California. Since its incorporation in 2010, Coherus BioSciences has established itself as a pivotal player in the biopharmaceutical field through its diverse product pipeline and strategic partnerships. It has engaged in multiple collaboration and licensing agreements, including with Junshi Biosciences for toripalimab, as well as Surface, Adimab LLC, Bioeq AG, Genentech, Inc., Vaccinex, Inc., Novartis Institutes for Biomedical Research, Inc., and GlaxoSmithKline Intellectual Property No. 4 Limited, thereby bolstering its research, development, and commercialization capabilities.
Products and Services
- UDENYCA: A biosimilar to Neulasta, UDENYCA aids in managing neutropenia, a common side effect of cancer treatment characterized by a decreased number of white blood cells. It is a long-acting granulocyte-colony stimulating factor that helps in reducing the duration of neutropenia.
- LOQTORZI: This novel PD-1 inhibitor represents a class of drugs designed to block the PD-1 receptor, a protein that prevents the immune system from attacking cancer cells. LOQTORZI is engineered for the treatment of various cancers by enhancing the body's immune response against tumor cells.
- Casdozokitug: An investigational recombinant human IgG1 monoclonal antibody targeting interleukin 27. It's being developed for its potential in cancer immunotherapy, focusing on the body's natural defense mechanisms to recognize and attack tumor cells.
- CHS-114: An investigational human afucosylated IgG1 monoclonal antibody with high specificity for CCR8. This antibody aims to target and diminish Treg cells in the tumor microenvironment, which are known to suppress the immune system's ability to fight cancer.
- CHS-1000: Targeting human ILT4, CHS-1000 is an antibody in development intended to modulate the tumor microenvironment from being cancer-favorable to one that supports immune system attack on cancer cells, thereby enhancing the efficacy of existing anti-PD-1 therapies.
- Immuno-Oncology Programs: Coherus BioSciences’ immuno-oncology portfolio includes NZV930, an antibody inhibiting CD73 to potentiate anti-tumor immunity, and GSK4381562, an antibody targeting CD112R for the treatment of solid tumors. These programs underscore the company’s dedication to developing novel interventions to enhance cancer patient outcomes.
- YUSIMRY: A biosimilar to Humira, YUSIMRY is designed for patients suffering from inflammatory diseases, such as rheumatoid arthritis and psoriasis, which are characterized by an overproduction of tumor necrosis factor (TNF) in the body. It offers a therapeutic alternative for managing these conditions.
